Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/11287
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKlein, Oliveren
dc.contributor.authorSchmidt, Christopheren
dc.contributor.authorKnights, Ashley Jen
dc.contributor.authorDavis, Ian Den
dc.contributor.authorChen, Weisanen
dc.contributor.authorCebon, Jonathan Sen
dc.date.accessioned2015-05-16T00:52:35Z
dc.date.available2015-05-16T00:52:35Z
dc.date.issued2011-06-01en
dc.identifier.citationExpert Review of Vaccines; 10(6): 853-73en
dc.identifier.govdoc21692705en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/11287en
dc.description.abstractDecades of preclinical evaluation and clinical trials into melanoma vaccines have yielded spectacular progress in our understanding of melanoma antigens and the immune mechanisms of tumor rejection. Key insights and the results of their clinical evaluation are reviewed in this article. Unfortunately, durable clinical benefit following vaccination remains uncommon. Two recent clinical advances that will impact on melanoma vaccine development are trials with inhibitors of CTLA-4 and oncogenic BRAF. Long-term therapeutic control of melanoma will require integration of specific active immunotherapy with these emerging successful therapies from the disparate fields of immune regulation and signal transduction.en
dc.language.isoenen
dc.subject.otherAntigens, CD.immunologyen
dc.subject.otherCTLA-4 Antigenen
dc.subject.otherCancer Vaccines.administration & dosage.immunologyen
dc.subject.otherClinical Trials as Topicen
dc.subject.otherHumansen
dc.subject.otherMelanoma.immunology.therapyen
dc.subject.otherProto-Oncogene Proteins B-raf.antagonists & inhibitors.immunologyen
dc.subject.otherTreatment Outcomeen
dc.titleMelanoma vaccines: developments over the past 10 years.en
dc.typeJournal Articleen
dc.identifier.journaltitleExpert review of vaccinesen
dc.identifier.affiliationLudwig Institute for Cancer Research, Austin Branch, Austin Hospital, Studley Road, Heidelberg, Victoria, 3084, Australiaen
dc.identifier.doi10.1586/erv.11.74en
dc.description.pages853-73en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/21692705en
dc.type.austinJournal Articleen
local.name.researcherCebon, Jonathan S
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptMedical Oncology-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

28
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.